alexsl
Viking Therapeutics (NASDAQ:VKTX) misplaced ~38% within the premarket on Tuesday after saying that its oral pill formulation of its GLP-1/GIP twin receptor agonist VK2735 induced as much as 12.2% of weight reduction over 13 weeks in a mid-stage trial.
Citing topline
